STAT

Alex Azar, Trump’s HHS nominee, says addressing drug prices would be his top priority

The message was aimed directly at Democrats and consumer groups, who have questioned whether he would deliver on Trump's promise to bring down prices.
Alex Azar, President Trump's pick to lead HHS.

WASHINGTON — Alex Azar, President Trump’s pick to lead the Health and Human Services Department, didn’t mince words when he described his top priority for the agency, telling lawmakers Wednesday that drug prices are too high and must be lowered.

“The president has made this clear, so have I,” Azar said.

The message was aimed directly at Democrats and critical consumer groups, who have questioned whether Azar would use his post to deliver on Trump’s campaign promise to bring down in particular.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks